Metastatic uveal melanoma (UM) is a poor prognosis malignancy. Immunotherapy is
commonly employed, despite the low activity, considering the lack of other effective systemic …

No standard treatment has been established for metastatic uveal melanoma (mUM).
Immunotherapy is commonly used for this disease even though UM has not been included …

Background Metastatic uveal melanoma (MUM) is associated with poor survival and inferior
response to immune checkpoint inhibitor (ICI) therapy when compared with metastatic …

Introduction Uveal melanoma (UM) is the most common intraocular cancer and represents a
discrete subtype of melanoma. Metastatic disease, which occurs in half of patients, has a …

Background To date, no systemic therapy, including immunotherapy, exists to improve
clinical outcomes in metastatic uveal melanoma (UM) patients. To understand the role of …

The low response rates to immunotherapy in uveal melanoma (UM) sharply contrast with
reputable response rates in cutaneous melanoma (CM) patients. To characterize the …

Introduction Despite recent advancements in the treatment of metastatic uveal melanoma
(UM), the availability of further treatment options remains limited and the prognosis …

This study aimed to identify prognostic factors in patients with metastatic uveal melanoma
(UM) that were associated with long-term survival in a real-world setting. A total of 94 …

Simple Summary Uveal melanoma is a rare form of melanoma but is the most common
tumor in the eye. Despite having effective treatments for the initial tumor, many patients …

Background Uveal melanoma (UM) represents the most common primary intra-ocular
malignancy in adults. Up to 50% of the patients develop distant metastases within 10 years …